- Company
- Myelofibrosis new drug Inrebic can be prescribed
- by Eo, Yun-Ho Apr 24, 2023 05:52am
- The Myelofibrosis drug Inrebic is now available for prescription in general hospitals. According to related industries, Inrevic, a myelofibrosis treatment drug from BMS Pharmaceuticals, passed the Drug Committee (DC) of general hospitals such as SMC and Seoul St. Mary's Hospital. Inrebic received domestic approval in April of last year as 't
- Company
- Will reimb limitations for Xospata be resolved this time?
- by Eo, Yun-Ho Apr 24, 2023 05:52am
- Whether Xospata will be able to produce results and receive reimbursement extensions this time is gaining attention. Dailpharm’s coverage showed that the agenda on expanding reimbursement standards for Xospata will likely be deliberated by the Health Insurance Review and Assessment Service(HIRA) Cancer Disease Deliberation Committee. The
- Company
- Hanmi Pharm, leading the outpatient prescription market
- by Chon, Seung-Hyun Apr 24, 2023 05:52am
- Hanmi Pharmaceutical continued its strong performance in the outpatient prescription market. With self-developed new complex drugs such as Rosuzet and Amosartan, it has been at the forefront of domestic and foreign pharmaceutical companies. Chong Kun Dang and Daewoong Pharmaceutical took the lead with high growth, while Daewoong Bio showed a ste
- Company
- Dong-A ST, preclinical results for immuno-cancer drugs
- by Kim, Jin-Gu Apr 23, 2023 09:44pm
- Dong-A ST announced on the 20th that it announced the results of a preclinical study of the immuno-cancer drug candidate "DA-4505" at the American Association for Cancer Research, AACR) 2023 held in Orlando, Florida from the 14th to the 19th. The American Cancer Research Association is called the world's top three cancer societies, and is an
- Company
- Patent dispute for Soliris faces 2nd trial/original company
- by Kim, Jin-Gu Apr 23, 2023 08:22pm
- The dispute over Soliris patents between Samsung Bioepis and Alexion will be dealt with in the second trial. According to the pharmaceutical industry on the 19th, Alexion recently filed a lawsuit against Samsung Bioepis to cancel the trial decision. Alexion registered two Soliris patents. However, among the two patents, the composition patent
- Company
- Pfizer Launches 'Pfizer Pro', a Customized Digital Platform
- by Eo, Yun-Ho Apr 23, 2023 07:48pm
- Pfizer Pharmaceutical Korea (CEO Oh Dong-wook) announced on the 12th that it has launched an integrated digital platform "Pfizer PRO" for health and medical experts to strengthen its Omni-Channel strategy. Pfizer Pro can be easily subscribed to by any health care professional and provides optimal content according to the preferred channel and
- Company
- Piqray to soon be deliberated by CDDC for reimb
- by Eo, Yun-Ho Apr 21, 2023 05:55am
- Whether reimbursement discussions for the PIK3CA gene-targeting anticancer drug ‘Piqray’ will make progress is gaining attention. According to industry sources, Novartis Korea’s Piqray (alpelisib) is expected to be deliberated at the coming Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee meeting.
- Company
- Expansion of reimbursement for DM drugs
- by Moon, sung-ho Apr 20, 2023 05:58am
- Amid the expansion of reimbursement criteria between diabetes treatments by class from April, attention is focused on the expansion of the two-drug combination of SGLT-2 inhibitor and DPP-4 inhibitor. This is because pharmaceutical companies are waiting for a reimbursement after receiving approval for a combination of DPP-4 inhibitor + SGLT-
- Company
- New heart failure drug Verquvo lands at general hospitals
- by Eo, Yun-Ho Apr 20, 2023 05:58am
- The new heart failure drug ‘Verquvo’ can now be prescribed at general hospitals in Korea. According to industry sources, Bayer Korea’s soluble guanylate cyclase (sGC) stimulator that catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), Verquvo (vericiguat) has passed the drug committees (DCs) of medical insti
- Company
- Will Lixiana follow-ons take over the market?
- by Moon, sung-ho Apr 19, 2023 05:51am
- Activity in related markets has been rising due to the aftermath of the reimbursement approval for Transcatheter Aortic Valve Implantation (TAVI) that had been made last year. Pharmaceutical companies have been increasingly conducting activities to target the Non-vitamin K antagonist oral anticoagulant (NOAC) market. According to indu
